These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25738527)

  • 21. Efficacy of pulse dexamethasone in non-systemic juvenile idiopathic arthritis: a double-blind randomized controlled trial.
    Bhardwaj U; Bagri NK; Lodha R; Kabra SK; Velpandian T; Pandey RM
    Rheumatology (Oxford); 2022 Aug; 61(8):3370-3377. PubMed ID: 34888654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
    Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J; Genovese M; Cannon GW; Caldwell J; Cush J; Furst DE; Luggen M; Keystone E; Bathon J; Kavanaugh A; Ruderman E; Coleman P; Curtis D; Kopp E; Kantor S; Weisman M; Waltuck J; Lindsley HB; Markenson J; Crawford B; Fernando I; Simpson K; Strand V
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
    Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
    J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
    Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
    Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leflunomide treatment in juvenile idiopathic arthritis.
    Ayaz NA; Karadağ ŞG; Çakmak F; Çakan M; Tanatar A; Sönmez HE
    Rheumatol Int; 2019 Sep; 39(9):1615-1619. PubMed ID: 31327053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
    Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
    Ruperto N; Lovell DJ; Cuttica R; Woo P; Meiorin S; Wouters C; Silverman ED; Balogh Z; Henrickson M; Davidson J; Foeldvari I; Imundo L; Simonini G; Oppermann J; Xu S; Shen YK; Visvanathan S; Fasanmade A; Mendelsohn A; Martini A; Giannini EH; ;
    Ann Rheum Dis; 2010 Apr; 69(4):718-22. PubMed ID: 20237125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.
    Imagawa T; Takei S; Umebayashi H; Yamaguchi K; Itoh Y; Kawai T; Iwata N; Murata T; Okafuji I; Miyoshi M; Onoe Y; Kawano Y; Kinjo N; Mori M; Mozaffarian N; Kupper H; Santra S; Patel G; Kawai S; Yokota S
    Clin Rheumatol; 2012 Dec; 31(12):1713-21. PubMed ID: 23053683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
    Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
    Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.
    van Dijkhuizen EH; Pouw JN; Scheuern A; Hügle B; Hardt S; Ganser G; Kümmerle-Deschner JB; Horneff G; Holzinger D; Bulatović Ćalasan M; Wulffraat NM
    Clin Exp Rheumatol; 2016; 34(1):148-54. PubMed ID: 26843067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis.
    Ravelli A; Moretti C; Temporini F; Rossi F; Magni-Manzoni S; Pistorio A; Martini A
    Clin Exp Rheumatol; 2002; 20(4):569-72. PubMed ID: 12175118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
    Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.